	Application No.	Applicant(s)
Notice of Allowability	09/909,062	SAKSENA ET AL.
	Examiner	Art Unit
	Maury Audet	1654
The MAILING DATE of this communication app ars on the cover sh t with the correspondenc address All claims being allowable, PROSECUTION ON THE MERITS IS (OR REMAINS) CLOSED in this application. If not included herewith (or previously mailed), a Notice of Allowance (PTOL-85) or other appropriate communication will be mailed in due course. THIS NOTICE OF ALLOWABILITY IS NOT A GRANT OF PATENT RIGHTS. This application is subject to withdrawal from issue at the initiative of the Office or upon petition by the applicant. See 37 CFR 1.313 and MPEP 1308.		
 This communication is responsive to 9/29/2003. The allowed claim(s) is/are 40. The drawings filed on are accepted by the Examiner. Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). All Some* None The drawings filed on are accepted by the Examiner. Cknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f). All Certified copies of the priority documents have been received. 		
2. Certified copies of the priority documents have been received in Application No		
Copies of the certified copies of the priority documents have been received in this national stage application from the International Bureau (PCT Rule 17.2(a)). * Certified copies not received:		
5. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application) since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78. (a) The translation of the foreign language provisional application has been received.		
6. Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121 since a specific reference was included in the first sentence of the specification or in an Application Data Sheet. 37 CFR 1.78.		
Applicant has THREE MONTHS FROM THE "MAILING DATE" of this communication to file a reply complying with the requirements noted below. Failure to timely comply will result in ABANDONMENT of this application. THIS THREE-MONTH PERIOD IS NOT EXTENDABLE.		
7. A SUBSTITUTE OATH OR DECLARATION must be submitted. Note the attached EXAMINER'S AMENDMENT or NOTICE OF INFORMAL PATENT APPLICATION (PTO-152) which gives reason(s) why the oath or declaration is deficient.		
 8. ☐ CORRECTED DRAWINGS (as "replacement sheets") must be submitted. (a) ☐ including changes required by the Notice of Draftsperson's Patent Drawing Review (PTO-948) attached 1) ☐ hereto or 2) ☐ to Paper No 		
(b) ☐ including changes required by the proposed drawing correction filed, which has been approved by the Examiner.		
(c) including changes required by the attached Examiner's Amendment / Comment or in the Office action of Paper No		
Identifying indicia such as the application number (see 37 CFR 1.84(c)) should be written on the drawings in the front (not the back) of each sheet. Replacement sheet(s) should be labeled as such in the margin according to 37 CFR 1.121(d).		
9. DEPOSIT OF and/or INFORMATION about the deposit of BIOLOGICAL MATERIAL must be submitted. Note the attached Examiner's comment regarding REQUIREMENT FOR THE DEPOSIT OF BIOLOGICAL MATERIAL.		
Attachment(s)		
1☐ Notice of References Cited (PTO-892)	5⊡ Notice of Informal Pa	tent Application (PTO-152)
 2☐ Notice of Draftperson's Patent Drawing Review (PTO-948) 3☑ Information Disclosure Statements (PTO-1449 or PTO/SB/08 Paper No. 1/3/02, & 	· • • • • • • • • • • • • • • • • • •	PTO-413), Paper No
	7⊠ Examiner's Amendm	ent/Comment
4☐ Examiner's Comment Regarding Requirement for Deposit of Biological Material	8□ Examiner's Statemen 9□ Other	nt of Reasons for Allowance

IDS Cont. 7/18/02, and 9/2/03

Art Unit: 1654

EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it MUST be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Harvey Cohen, Attorney for Applicant, on December 10, 2003.

IN THE CLAIMS

Claim 40 has been cancelled and replaced with the following claim, claim 55.

-- 55. A compound exhibiting HCV protease inhibitory activity, including enantiomers, stereoisomers, rotamers and tautomers of said compound, and pharmaceutically acceptable salts or solvates of said compound, said compound being selected from the group of compounds with structures listed below:

Application/Control Number: 09/909,062

Art Unit: 1654

Art Unit: 1654

Application/Control Number: 09/909,062 Page 5

Art Unit: 1654

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Conclusion

Claim 40 is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maury Audet whose telephone number is 703-305-5039. The examiner can normally be reached from 7:00 AM - 5:30 PM, off Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Brenda Brumback can be reached at 703-306-3220. The fax phone numbers for the organization where this application or proceeding is assigned are 703-308-4242 for regular communications and 703-308-1234 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is 703-308-1235.

MA December 10, 2003

> CHRISTOPHER R. TATE PRIMARY EXAMINER